Tag Archives: gsk
GlaxoSmithKline’s Anthrax Drug Wins Thumbs Up From FDA Panel
LONDON (dpa-AFX) – GlaxoSmithKline plc (GSK) announced Friday that an FDA panel of experts has voted in favor of its investigational medicine for anthrax, Raxibacumab.According to the company, the… Continue reading
Is Being Unethical Worth It?: Opinion
NEW YORK (TheStreet) — Within the last few days of writing this commentary, and prior to celebrating our July Fourth independence, two significant scandals have been resolved, one in the banking industry and another in pharmaceuticals. GlaxoSmithKline agreed to plead guilty to misdemeanor criminal charges and pay $3 billion to settle what government officials described as the largest case of health care fraud in U.S. history. Continue reading
GSK Report Data From PhaseIII Study Of Once-weekly Albiglutide In Type2 Diabetes
LONDON (dpa-AFX) – GlaxoSmithKline Plc (GSK, GSK.L) announced new 52-week data from phase III study of once-weekly albiglutide in type 2 diabetes. The company said that detailed findin… Continue reading
ASCO ’12: Roche, ImmunoGen Drug Delays Breast Tumor Growth
CHICAGO (TheStreet) — An experimental antibody-drug conjugate therapy from the Genentech unit of Roche delayed by more than three months the re-growth of breast cancer compared to the current standard of care, according to a phase III study being presented today at the American Society of Clinical Oncology (ASCO) annual meeting. The drug, known as T-DM1, will be filed for regulatory approval in the U.S. and Europe later this year, Roche said Continue reading
Upcoming Economic Outlook – Report Highlights GlaxoSmithKline plc (ADR) and Bristol Myers Squibb Co.
HONG KONG–(Marketwire – Jun 1, 2012) – Today, www.BrightonMarkets.com announced new reports highlighting GlaxoSmithKline plc (ADR) ( NYSE : GSK ) and Bristol Myers Squibb Co. ( NYSE : BMY ). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=GSK&cob=BMY . Continue reading
Upcoming Economic Outlook – Report Highlights GlaxoSmithKline plc (ADR) and Bristol Myers Squibb Co.
HONG KONG–(Marketwire – Jun 1, 2012) – Today, www.BrightonMarkets.com announced new reports highlighting GlaxoSmithKline plc (ADR) ( NYSE : GSK ) and Bristol Myers Squibb Co. Continue reading
Bristol Drug Unlocks Immune System to Shrink Tumors
CHICAGO (TheStreet) – -An experimental drug from Bristol-Myers Squibb that helps the immune system attack cancer cells was able to shrink tumors in patients with melanoma, kidney and non-small cell lung cancers, according to results from an early-stage study being presented later today at the American Society of Clinical Oncology (ASCO) annual meeting. The promising Bristol drug, BMS-936658, follows in the footsteps of Yervoy, another Bristol drug that was approved last year to treat melanoma and which also harnesses the power of a patient’s immune system to fight cancer. Bristol is accelerating development of ’658 and will push the drug into pivotal, phase III studies in lung cancer, melanoma and kidney cancer, based in part of the data presented at this year’s ASCO meeting Continue reading
The Next Big Thing in Biotech: M&A
Senior columnist Adam Feuerstein says M&A is the next big thing in biotech. Continue reading
Vaccines group gets cut-price GSK, Merck rotavirus shots
LONDON (Reuters) – International vaccines group GAVI has struck a deal for bulk buying rotavirus shots from GlaxoSmithKline and Merck which cuts the price by two-thirds and will allow poorer countries access to them at around $5 per course. The vaccines, GSK’s Rotarix and Merck’s Rotateq, combat the main cause of diarrhea – the second-largest killer of children under the age of five worldwide. … Continue reading
10 Dividend Stocks Held by Highly Rated Fund Managers (Update1)
(Story updated to add that Eli Lilly’s CEO said the company wants to be the fastest-growing drug company in China.) BOSTON (TheStreet) — Concerns that a stock market correction is overdue may be turning investors, particularly those near or in retirement, into yield hounds. And since dividends on fixed-income securities are still at historically low levels, with the yield on 10-year U.S. Treasuries at less than 2.5%, they would do best to look for stocks with growing dividends being paid by high-quality companies, both for their yield and their potential share-price appreciation Continue reading
